NCT03041363View on ClinicalTrials.gov

Treatment Development of Triheptanoin (G1D)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 29, 2017

Primary Completion Date

December 22, 2017

Study Completion Date

December 22, 2017

Conditions

EpilepsyGLUT1DS1Glut1 Deficiency Syndrome 1, Autosomal RecessiveGlucose Metabolism DisordersGlucose Transport DefectGlucose Transporter Type 1 Deficiency SyndromeGlucose Transporter Protein Type 1 Deficiency Syndrome

Interventions

DRUG

Triheptanoin

Triheptanoin will be administered for 7 days 4 times daily.

Trial Locations (1)

75390

UT Southwestern Medical Center, Dallas

All Listed Sponsors

collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

Juan Pascual

OTHER

NCT03041363 - Treatment Development of Triheptanoin (G1D) | Biotech Hunter | Biotech Hunter